Acta Obstetricia et Gynecologica Scandinavica
Hormone therapy after ovarian cancer not linked to worse survival
For epithelial ovarian cancer, which starts in lining cells, adjusted 10-year survival was 52.4% among hormone users versus 51.7% among non-users.For epithelial ovarian cancer, which starts in lining cells, adjusted 10-year survival was 52.4% among hormone users versus 51.7% among non-users.
Cohort · 454 peopleOvarian cancer
Who was studied454 women with epithelial ovarian cancer, median 11.7 years
What changedFollowing ovarian cancer surgery, 10-year survival did not differ: 52.4% with hormone therapy versus 51.7% without it
The catchSmoking, BMI, and other illnesses affecting survival were missing from the analysis